Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Tabuk University, Tabuk,Saudi Arabia.
Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Albaha University, Albaha,Saudi Arabia.
Endocr Metab Immune Disord Drug Targets. 2021;21(11):1949-1953. doi: 10.2174/1871530321999201228214718.
COVID-19 (Virus named as severe acute respiratory syndrome coronavirus 2 (SARS-- CoV-2)) is a pandemic disease characterized by respiratory infection caused by a coronavirus. It has spread worldwide after an outbreak began in Wuhan, China, in December 2019. SARS-CoV-2 has infected more than 15 million people globally. The disease severity and mortality increased in patients with heart-related comorbidities. Cardiovascular disease patients are more susceptible and infected with SARS-CoV-2. Early screening and management of these patients prevent or ameliorate adverse outcomes. Several treatments have been used to combat these effects, as previously seen in MERS and SARS. This review will cover the association of cardiovascular diseases with COVID 19. It showed that cardiovascular diseases are common in patients with COVID- 19. Increased attention to highlight the gaps should be paid to the care of this unique group of patients.
新型冠状病毒肺炎（COVID-19，由严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）引起）是一种以冠状病毒引起的呼吸道感染为特征的大流行疾病。它于 2019 年 12 月在中国武汉爆发后，在全球范围内传播。SARS-CoV-2 已在全球感染超过 1500 万人。有心脏相关合并症的患者疾病严重程度和死亡率增加。心血管疾病患者更容易感染 SARS-CoV-2。早期筛查和管理这些患者可以预防或改善不良结局。以前在中东呼吸综合征（MERS）和严重急性呼吸综合征（SARS）中已经使用了几种治疗方法来对抗这些影响。这篇综述将涵盖心血管疾病与 COVID-19 的关联。结果表明，心血管疾病在 COVID-19 患者中很常见。应更加关注并突出该特殊患者群体的护理差距。
